Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Biocon Pegfilgrastim Biosimilar Wins Japan Marketing Approval

Guavy AI Editorial Team
Instruments
AMGN
Share

Biocon has secured marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). The approval was confirmed on August 25, 2026.

The product is developed by Biocon Biologics Ltd. and serves as a biosimilar to Amgen's Neulasta.

Sandoz K.K. will exclusively promote, sell, and distribute the drug in Japan, allowing Biocon to leverage local distribution networks while focusing on manufacturing and regulatory compliance.

More on Stocks

Stocks just now

UK Public Sector Leaders Seek Clarity on Data Management for Modernised Services

Stocks 2m ago

Burundi's First Lady Receives Prestigious UN Population Award for Healthcare Contributions

Stocks 2m ago

Merck & Moderna's Cancer Vaccine Breakthrough Offers Hope for Patients

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy